CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 39 enrolled
Drug / intervention
Omeprazole +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03327051
NCT03327051Phase 4Completed

The Effect of Gastric Acid Suppression on Probiotic Colonization

Stanford University·interventional·Posted Oct 31, 2017·Updated Mar 11, 2020

In Brief

A Phase 4 clinical trial evaluating Omeprazole, VSL #3, and 1 other intervention for Probiotics. Completed, enrolled 39 participants across 1 site.

Detailed Summary

Probiotics are over-the-counter dietary products with microorganisms that are generally consumed for health benefit. However, the durability of these microorganisms is unclear, particularly when they pass through the highly acidic environment of the stomach. We will test the colonization of these microorganisms among individuals who consume probiotics with and without acid suppression therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProbiotics
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 31, 2017
Enrollment StartMar 20, 2018
Primary CompletionDec 30, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.7 years ago

Interventions

Omeprazoledrug

Proton pump inhibitor (PPI) that suppresses gastric acid secretion

VSL #3dietary

Probiotics

Placebodrug

Placebo to match omeprazole